Macquarie Group Ltd. reduced its stake in Hologic (NASDAQ:HOLX) by 99.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,600 shares of the medical equipment provider’s stock after selling 1,010,672 shares during the period. Macquarie Group Ltd.’s holdings in Hologic were worth $254,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in HOLX. Parnassus Investments CA raised its stake in shares of Hologic by 88.6% in the fourth quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock valued at $608,797,000 after acquiring an additional 6,689,454 shares in the last quarter. Two Sigma Advisers LP raised its stake in shares of Hologic by 28.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,828,311 shares of the medical equipment provider’s stock valued at $120,910,000 after acquiring an additional 620,761 shares in the last quarter. Guggenheim Capital LLC raised its stake in shares of Hologic by 46.0% in the fourth quarter. Guggenheim Capital LLC now owns 1,662,053 shares of the medical equipment provider’s stock valued at $71,053,000 after acquiring an additional 523,654 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Hologic in the fourth quarter valued at $18,383,000. Finally, Victory Capital Management Inc. raised its stake in shares of Hologic by 5.8% in the fourth quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock valued at $265,008,000 after acquiring an additional 342,239 shares in the last quarter. Institutional investors and hedge funds own 97.56% of the company’s stock.
HOLX has been the topic of several analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $48.00 price objective on shares of Hologic in a research note on Friday, February 9th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a research note on Friday, February 9th. Bank of America upgraded Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price objective on the stock in a research note on Thursday, January 4th. Cowen upgraded Hologic to a “buy” rating and set a $52.00 price objective on the stock in a research note on Wednesday, December 20th. Finally, Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research note on Tuesday, February 13th. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. Hologic has an average rating of “Buy” and an average price target of $47.21.
In other news, Director Namal Nawana acquired 6,600 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were bought at an average price of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now owns 6,954 shares in the company, valued at approximately $263,417.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Charles J. Dockendorff acquired 13,000 shares of the company’s stock in a transaction on Thursday, March 15th. The shares were purchased at an average cost of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. Corporate insiders own 0.79% of the company’s stock.
NASDAQ:HOLX opened at $37.02 on Monday. The firm has a market capitalization of $10,245.40, a P/E ratio of 18.24, a price-to-earnings-growth ratio of 1.67 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. Hologic has a 12 month low of $35.33 and a 12 month high of $46.80.
Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. Hologic had a return on equity of 20.07% and a net margin of 34.53%. Hologic’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 earnings per share. analysts predict that Hologic will post 2.25 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/16/macquarie-group-ltd-has-254000-stake-in-hologic-holx.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.